Eurand NV Financial Statements
Eurand NV Financial Information
| Company Type | Public |
|---|---|
| Fiscal Year-End | December |
This data is provided as per license from EDGAR Online
Eurand NV Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 123.9 | 109.3 | 85.6 |
| Gross Profit ($ mil.) | 51.7 | 46.6 | 33.3 |
| Operating Income ($ mil.) | (6.0) | 5.1 | 0.4 |
| Total Net Income ($ mil.) | (9.8) | (6.6) | (9.8) |
| Diluted EPS (Net Income) | (0.35) | -- | -- |
Eurand NV Stock Quote & Chart
08/29/08 15:00:04 EST •
NASDAQ •
16.57
•
 +0.0300
•
+0.1814 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Eurand NV Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 6.40 | 3.69 | 1.54 |
| Price/Earnings Ratio | -- | 15.22 | 15.51 |
| Price/Book Ratio | 6.69 | 2.94 | 1.48 |
| Price/Cash Flow Ratio | 301.71 | 12.49 | 9.68 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Eurand NV Financial Ratios
Eurand NV Competitive Intelligence
| Axcan Pharma | Elan | K-V Pharmaceutical | |
|---|---|---|---|
| Annual Sales ($ mil.) | 349.0 | 759.4 | 601.9 |
| Employees | 480 | -- | -- |
| Market Cap ($ mil.) | -- | -- | 828.9 |
Competitive Landscape
